Skip to main content

Table 2 Mean changes in HRQoL scores from baseline to study phase completion (week 16) by ACR improvement categories, all dose groups combined

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

  ACR < 20% (n = 100) ACR 20-49% (n = 49) ACR 50-69% (n = 24) ACR 70% (n = 9) F p-value
PRO Instruments       
SF-36       
Physical functioning 2.1 (15.6) 8.5 (17.2) 17.9 (18.5) 24.4 (28.4) 9.1 0.0000
Role physical 2.7 (17.3) 12.8 (22.5) 23.9 (23.5) 27.8 (35.2) 10.2 0.0000
Bodily pain 0.4 (14.7) 18.1 (16.6) 24.0 (19.0) 39.1 (13.2) 33.1 0.0000
General health -1.9 (12.7) 4.7 (12.8) 15.9 (13.6) 18.7 (11.3) 17.7 0.0000
Vitality 0.1 (16.1) 9.9 (19.6) 18.5 (21.1) 29.9 (24.8) 13.2 0.0000
Social functioning -1.5 (23.9) 12.8 (21.9) 7.8 (27.0) 29.2 (37.0) 7.0 0.0000
Role emotional -2.1 (22.5) 8.9 (27.2) 13.5 (26.6) 29.6 (27.0) 7.1 0.0000
Mental health -0.2 (15.2) 6.8 (16.5) 9.4 (23.6) 23.9 (23.0) 7.2 0.0000
Physical summary 0.8 (4.9) 4.6 (5.9) 9.3 (6.1) 10.1 (10.3) 20.8 0.0000
Mental summary -1.0 (8.9) 4.0 (9.3) 4.3 (12.9) 13.7 (16.0) 8.1 0.0000
FACIT-Fatigue 0.6 (7.2) 5.7 (7.2) 8.8 (8.0) 11.3 (4.5) 14.9 0.0000